Of 41 patients with bone-related infections who were treated for у10 days with piperacillin-tazobactam, 14 (34%) developed neutropenia. Cumulative doses of piperacillin administered to neutropenic patients were higher than those administered to nonneutropenic ones (330 vs. 237 g; P p ), and an inverse correlation was detected between the .008 absolute neutrophil count at the end of treatment and the cumulative dose of piperacillin ( , ). Morer p Ϫ0.47 P p .002 over, the incidence of piperacillin-tazobactam-induced neutropenia increased with an increase in the cumulative dose of piperacillin: 0% of patients in the first quartile of cumulative piperacillin doses, 33.3% in the second quartile, 40% in the third quartile, and 66.7% in the fourth quartile.
B R I E F R E P O R T

Incidence of Neutropenia during Treatment of Bone-Related Infections with Piperacillin-Tazobactam
The standard therapy for bone infections involves prolonged treatment using high doses of antibiotics [1] . Piperacillintazobactam, a combination of a semisynthetic ureidopenicillin and a b-lactamase inhibitor, has broad-spectrum activity and is useful in treating polymicrobial and gram-negative bacterial infections [2] [3] [4] , including diabetic foot infections [5] and osteomyelitis [1, 6] . b-Lactam antibiotics, in general [7] [8] [9] [10] [11] , and piperacillin [9] and piperacillin-tazobactam, in particular [10] , can lead to reversible neutropenia in patients receiving treatments lasting 110 days [11] . Although the incidence of neutropenia induced by treatment with b-lactam antibiotics has been studied in relation to such infections as endocarditis [8, 12] , cystic fibrosis [13] , and osteomyelitis [9] , little information is available on the side effects of prolonged therapy with piperacillin-tazobactam in patients with bone-related infec-tions. The present study assesses the incidence of piperacillintazobactam-related neutropenia among patients receiving prolonged treatments for bone-related infections.
Materials and methods. The hospital records of patients who received a diagnosis of bone-related infection and were admitted to Sierrallana Hospital (Torrelavega, Cantabria, Spain) and University Hospital Marqués de Valdecilla (Santander, Cantabria, Spain) from January 1995 to December 2001 were reviewed. Of a total of 209 such patients, 16 received treatment for bone-related infection during 2 different hospital stays, 4 patients during 3 different hospital stays, and 1 patient during 4 different hospital stays. In assessing the incidence of neutropenia induced by piperacillin-tazobactam, only cases treated with this antibiotic for у10 days were evaluated. Patients with hematological diseases or HIV infection were excluded from the analysis.
Fever was defined as an axillary temperature of у37.8ЊC found on у2 occasions. Neutropenia was defined as an absolute neutrophil count of р2000 cells/mm 3 . Anemia was defined as a hemoglobin concentration of !12 g/dL. Thrombocytopenia was defined as a platelet count of !150,000 platelets/mm 3 . Eosinophilia was defined as an absolute count in peripheral blood of у500 eosinophils/mm 3 . Neutropenia was considered severe if the absolute neutrophil count was !500 cells/mm 3 . Renal failure was defined as a creatinine concentration of 11.5 mg/ dL in plasma. An adverse reaction was considered to be related to piperacillin-tazobactam if the reaction had not been present before the administration of piperacillin-tazobactam therapy and had disappeared after therapy was discontinued, and if other possible causes for the adverse reaction were discarded. The diagnosis of bone infection was made on the basis of radiological, scintigraphical, and histopathological data. If signs of infection were found and bone or an orthopedic device was visibly exposed, the existence of a bone-related infection was assumed.
In statistical analyses, a 2-tailed Student's t test was used for the comparison of mean values, Fisher's exact test and the x 2 test were used for the assessment of proportions, and Pearson's correlation coefficient was used to explore the correlation between 2 variables.
Results. The records of 236 hospitalizations (209 patients) with the diagnosis of bone infection were reviewed. Of these, the records of 43 cases (40 patients, 3 of whom had been hospitalized twice) in which the infection was treated with piperacillin-tazobactam for у10 days were analyzed. Two cases were excluded from the study because no hematological control Diabetic foot 24 6 Use of orthopedic device 0 4
By causal microorganism
Pseudomonas aeruginosa 6 6
Escherichia coli 1 0
Enterobacter cloacae 0 1
Enterococcus faecalis 1 0
Proteus mirabilis 1 0
Serratia marcescens 0 1
Stenotrophomonas species 1 0
Staphylococcus aureus 1 0
Streptococcus agalactiae 0 1 Polymicrobial 5 5 was performed in the last 5 days of piperacillin-tazobactam treatment; therefore, only 41 cases were included in the assessment. In all cases, the prescribed dose of piperacillintazobactam was 4 g of piperacillin and 0.5 g of tazobactam, with an interval that was adjusted depending on the causal microorganism and the status of renal function. The original condition associated with each infection and the microorganisms isolated from each patient are shown in table 1. In 14 (34%) of the 41 cases treated with piperacillin-tazobactam, the patient developed neutropenia. In 4 of these cases, the neutropenia was severe, and 3 patients required treatment with granulocyte colony-stimulating factor. Neutropenia appeared after patients had received a mean of 26.8 days of therapy (range, 18-51 days) and a mean cumulative dose of 330.3 g of piperacillin (range, 204-612 g). The mean cumulative dose of piperacillin administered to the patients who developed neutropenia was significantly higher than that administered to the nonneutropenic group (table 2) . A significant inverse correlation was found between the cumulative dose of piperacillin administered and the neutrophil count obtained at the end of treatment ( figure 1) . Moreover, the proportion of patients with neutropenia clearly increased as the total cumulative dose of piperacillin-tazobactam increased (figure 2). Among the neutropenic group, 6 patients also developed thrombocytopenia, 9 developed anemia, and 3 developed eosinophilia. In 9 of the patients who developed neutropenia (including the 4 patients with severe neutropenia), fever preceded the hematological abnormalities by 1-7 days (mean, 3.7 days). Three patients developed a rash and 2 patients complained of an unpleasant sensation during administration of antibiotics in the days prior to the appearance of neutropenia.
No significant differences were found between the initial neutrophil counts of peripheral blood samples or the levels of creatinine or albumin in plasma of the patients who developed neutropenia and those of patients who did not. However, compared with patients who did not develop neutropenia, patients who developed neutropenia were younger, more of them had been treated with another antibiotic in association with piperacillin-tazobactam, and a lower proportion of them were diagnosed with diabetic foot infection ( ) (tables 2 and P p .003 3). Of the 4 patients with severe neutropenia, 3 were treated with piperacillin-tazobactam and another antibiotic simultaneously (1 patient with ciprofloxacin, 1 with gentamicin, and 1 with aztreonam). None of the patients had chronic liver disease. Discussion. In our study, the proportion of patients treated for bone-related infections with piperacillin-tazobactam who developed reversible neutropenia was high. Reviews of this antibiotic do not mention this side-effect, although they do describe its efficacy in long-term treatment of osteomyelitis [3] [4] [5] . Moreover, in a recent review of 21 cases of antibiotic-induced agranulocytosis, none of the cases reviewed were related to piperacillintazobactam therapy [14] . There is little information in the literature about the toxicity of prolonged piperacillin-tazobactam treatment for conditions such as bone-related infections, despite the fact that piperacillin-tazobactam therapy is considered one of the choices for treatment of osteomyelitis [1] and diabetic foot infection [15, 16] . One report about its efficacy in treating diabetic foot infection does not even mention cases of antibioticinduced neutropenia [5] .
Our data support the existence of a piperacillin-tazobactam dose-related toxicity. We found that the incidence of neutropenia increased as cumulative piperacillin doses increased. An inverse correlation between cumulative piperacillin dose and the neutrophil count at the end of therapy also supports this finding. No patient treated for !18 days, nor any with a cumulative dose of !204 g of piperacillin, developed neutropenia. Lang et al. [9] , using the same cutoff point for neutropenia that was used in this study, detected neutropenia in 38% of patients treated with broad-spectrum penicillins (including 6 patients treated with piperacillin) for bone infections, with a range of total cumulative piperacillin doses of 144-480 g. This proportion of patients with neutropenia and this range of total cumulative piperacillin doses are similar to those found in our series. Similarly, in the 3 cases of neutropenia induced by piperacillin-tazobactam in adults that have been reported elsewhere, therapy lasted for у17 days [10, 17, 18] .
Despite the fact that the duration of treatment determines the cumulative dose, differences between the mean treatment duration among neutropenic patients and that among nonneutropenic patients were not statistically significant, as shown in table 2. These data reflect a dissociation between the cumulative dose and the duration of the treatment. Bearing in mind that the mechanism of neutropenia is related to cumulative piperacillin doses, the piperacillin-tazobactam daily dosage should not be considered the same for all patients (most patients received piperacillin-tazobactam 3 times daily) and sometimes changes during treatment. The differences between groups are ameliorated because patients with renal insufficiency, who need a lower daily dose, are only found in the nonneutropenic group and receive a longer course of treatment to reach a particular cumulative dose than do patients without renal insufficiency.
The information about piperacillin-tazobactam-induced neutropenia comes into apparent conflict with previously published data on the incidence of hematological toxicity when high cumulative doses of piperacillin alone are administered. However, the length of piperacillin-tazobactam treatment described in published studies does not usually surpass 2 weeks [3] [4] [5] , including some recent trials dealing with patients with diabetic foot infection [19, 20] . Ruiz-Irastorza et al. [18] explain these apparent differences in the marrow toxicity of piperacillin and piperacillin-tazobactam by the difference in the amount of the usual daily dose (12 g, in the case of piperacillin, and 16 g, in the case of piperacillin-tazobactam). There may also be other factors influencing the development of piperacillin-tazobactam toxicity, and, indeed, our data suggest that age has an effect on the incidence of piperacillin toxicity. Among our patients, those who developed toxicity were younger, and 2 of the 3 cases in adults reported in the literature refer to young patients. Some investigators propose that piperacillin-tazobactam toxicity is greater in children [13] . In fact, in the 3 cases of piperacillintazobactam-induced neutropenia reported in children, toxicity developed after 11-15 days of treatment [13] , a shorter interval than that reported for adults. Another factor that may affect the incidence of toxicity related to b-lactams is the coexistence of severe hepatic dysfunction [21] , although piperacillin-tazobactam elimination is not altered by hepatic disease [3] , and no patient in our series had this problem. On the other hand, both piperacillin and tazobactam are eliminated in urine. Although the hypothesis is unproven, renal insufficiency may also facilitate piperacillintazobactam-induced neutropenia because of an increase in the level of antibiotics in plasma [3] . The incidence of renal failure, however, was even lower among patients who developed neutropenia than among those who did not. A fourth factor that may increase the toxic effect of the antibiotic is low concentrations of protein in plasma, because this produces a higher concentration of free antibiotics [3] . However, plasma albumin levels were not lower in our neutropenic patients than in our nonneutropenic patients.
Finally, the association of antibiotics with piperacillin-tazobactam was more frequent among our neutropenic patients than among our nonneutropenic patients. This may reflect the higher proportion of Pseudomonas species and polymicrobial infections found among these patients. Aztreonam, a b-lactam antibiotic that has a structural relationship with piperacillin, may theoretically facilitate neutropenia, although this is unlikely given that this toxicity is absent when aztreonam is administered alone [14, 22] . A contribution from teicoplanin, quinolones, or aminoglycosides to the development of neutropenia is also quite improbable [14, 23, 24] .
In conclusion, our data show a high incidence of antibioticinduced neutropenia among patients receiving prolonged piperacillin-tazobactam therapy for bone-related infections, with toxicity related to the cumulative dose. Frequent hematological control testing should be performed if therapy is administered for 12 weeks, particularly for younger patients. Fever or rash may precede neutropenia and, to prevent the development of severe cases, these clinical findings should be considered warning signs.
